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Continuing on its mission and conference series to raise awareness and understand 
paediatric-specific issues in the development of age appropriate dosage forms, the European 
Paediatric Formulation Initiative (EuPFI) convoked its 8th annual conference with the 
International Association of Pharmaceutical Technology (APV) on 21st and 22nd September 
2016 at the Hotel Novotel in Lisbon, Portugal. The participation of 158 delegates from 
Industry, Academia, Regulatory and other organisations from 26 countries with diverse 
backgrounds and involvement in both formulation development and regulatory submissions 
provided a productive setting for the exchange of information and views. 
 
The two pre-conference workshops provided much needed focus and interactive session to 
both the experienced and participants who were new to the area.  One on “Benefit risk 
approach to dosage form design for paediatrics” orchestrated by Dr. Jenny Walsh and team 
helped participants to identify the key components of the Quality Target Product Profile that 
influence the selection of a paediatric dosage form.  The workshop illustrated how it may be 
necessary to make compromises to certain elements of the design to ensure a product with 
acceptable ease of use, safety and patient access can be developed.  The participants were 
asked to utilise information provided on a fictional antibiotic to propose and justify an age 
appropriate product, taking into account the relative benefits and risks of potential dosage 
form options. In the second one Dr. Nassir Hussian introduced the regulatory 
framework/quality section of PIPs and the data package that comes into licensing division 
when the product has reached the market authorisation submission stage. 
 
The programme included a variety of thought-provoking and discussion-stimulating topics 
tailored specifically to paediatric product development with the patient’s point of view in 
mind. A shift has oocured in the culture of drug development with industry and regulatory 
agencies showing more interest in incorporating the perspectives of patients and innovative 
approaches in paediatric medicine development. In that respect, the conference opened with 
the plenary session by Simon Stones, the youngest presenter of the conference who gave the 
view of a young person on effectively engaging young patients people in the prioritisation and 
early clinical trial design stages to help the delivery of relevant research that addresses the 
unmet needs of young people and their families.  
 
There is a lot of effort going into developing medicines for children that are acceptable in 
terms of taste but also provide the relevant dose and exposure required for such patients. Dr 
Alastair Coupe shared how UK pharmaceutical companies, academia and technology suppliers 
are working collaboratively and innovatively to generate a structured approach to designing 
age-appropriate medicines for children and technology for predicting their quality and 
performance. He introduced the project SPaeDD-UK: Smart Paediatric Drug Development - 
UK Accelerating paediatric formulation development through smart design and predictive 
science” which aims to provide a smarter route to developing children’s medicines to reduce 
costs and time of development by determination of the most appropriate testing strategies 
that drive formulation design 
(http://www.paediatricscienceuk.com/store/c1/Featured_Products.html). 
Paediatric Investigation Plans (PIPs) are regulator’s main tool to ensure that previously unmet 
therapeutic needs in children are researched and that appropriate medicines are developed. 
All PIPs should address the need for specific forms suited to the targeted age group(s), and 
provide qualitative and quantitative information on the formulation proposed, with a 
thorough justification of its appropriateness. Dr. Brian Alyward shed the light on how to 
improve the quality and consistency of data submitted on paediatric pharmaceutical 
development in PIPs. 
 
The plenary talks were followed by thematic focus sessions addressing common current 
challenges (Excipients, Taste assessment and Taste Masking, Administration devices, Age 
appropriateness of formulations, and Biopharmaceutics) in paediatric product development.   
 
Age appropriate session chaired by Dr. Fang Liu (University of Hertfordshire, Uk) covered two 
talks one on Paediatric development for poorly water soluble drugs (PWSDs) and other on 
Medicine Acceptability in Children: An Original Tool for Standardized Evaluation. The 
landscape of how to deliver PWSDs for children is quite complex due to limitations in 
excipients (amounts), different physiology of the GI tract for paediatric populations and 
different drug delivery technologies. EuPFI Age Appropriate Workstream members are writing 
a position paper about paediatric approaches/strategies for PWSDs to get a better overview 
about the drug delivery landscape for these challenging molecules with regards to their 
administration in children. Dr. Carsten Timpe (F. Hoffmann-La Roche, Switzerland) introduced 
this paper and highlighted technical challenges and constraints in selecting the appropriate 
enhancing PWSD technology for a paediatric formulation such as short in-use times in case of 
solid dispersions, administration devices, safety of excipients, human factor (caregivers) with 
examples from marketed drug products.  
 
The concept of age-appropriateness is not limited to the selecting suitable technologies and 
development of age appropriate dosage forms but also needs to take into account patient 
acceptability to optimize patient adherence. Mr. Fabrice Ruiz presented an original 
standardised tool assessing the medicine's acceptability irrespective of their characteristics 
and the patient features1. The model is based on mapping and clustering processes providing 
relevant standardized acceptability assessments and comparison among medicines. Any 
medicine may be positioned on the acceptability map and defined by an acceptability profile 
using the barycentre of their evaluations. 
 
Dr. Gesine Winzenburg (Novartis, Swizerland) chaired the taste masking and taste assessment 
session. Unacceptable sensory properties such as bitterness of drug molecules present a 
major problem of compliance for children. Recognition of sensory issues in early stages of 
clinical development can help in selection of appropriate compounds and/or salt versions of 
compounds for further development. Two talks in this session presented different approaches 
for efficient prediction of compounds’ bitterness in the initial stages of drug discovery. Marco 
Cocorocchio presented a novel non-animal model to investigate taste-related responses i.e 
the amoeba Dictyostelium discoideum and particularly identification of compounds with a 
bitter taste liability. Exposing Dictyostelium to substances that evoke the five basic tastes in 
humans showed that it was only affected by the bitter tastants. Dr. Masha Niv presented 
computational in-silico approach towards bitterness prediction.  She introduced the BitterDB 
(Wiener et al., 2012), a freely accessible repository of compounds that were reported to be 
bitter for humans or to activate bitter taste receptors (Tas2Rs) in cell-based functional assays. 
 
The excipient’s focus session was chaired by Dr Floriane Sequier (AstraZeneca, Uk). Dr Dave 
Schonecker (Colorcon, IPEC America, US) provided the update on interactions between FDA, 
IPEC and IQ on the Inactive ingredient database (IID) and paediatric formulations. He 
highlighted some of the key issues with the IID identified by IPEC Americas that still needs to 
be addressed. These include updating the database, unclear requirements for how families of 
materials is handled and what data is needed to support safe use levels in Abbreviated New 
Drug Applications (ANDA). It is not possible to identify the maximum daily intake (MDI) of 
ingredients required for ANDAs. The IPEC Americas IID team has coordinated meetings to 
accelerate progress on these issues. Many changes have been made to the IID and FDA is still 
working on IID clean up process and is expected to make additional changes. He informed that 
FDA is developing a new database for inactive ingredients that will include information on 
MDI levels and there have also been discussions about possible benefits of including MDI 
levels for paediatrics.  
 
Dr. Massimo Montalto,  (Università Cattolica del Sacro Cuore,Italy) addressed several issues 
regarding use of lactose in medicines including lactose intolerance prevalence, health 
outcomes in association with lactose intake, genetic predisposition, lactose malabsorption 
and intolerance, and amount of lactose likely to be tolerable. The usefulness of different 
approaches to address these issues such as exogenous β-galactosidase, yogurt and probiotics 
for their bacterial lactase activity, pharmacological and non-pharmacological strategies were 
presented. Therapeutic strategies for managing lactose-intolerant individuals to ensure that 
they ingest calcium, vitamin D, and other nutrients found in dairy products were proposed. 
The suggestion was to gradually re-introduce dairy products considering the individual 
threshold dose and in order to raise the threshold dose, some non-pharmacological and 
pharmacological strategies should be considered2.  
 
Dr Jenny Walsh (Jenny Walsh Consulting Ltd, UK) chaired the administration devices session, 
which included talks on The Combination Product Development Roadmap by Dr Esmerald 
Hermans (Janssen Research & Development, Belgium) and Kinderleicht- Usability Testing with 
Kids by Torsten Gruchmann (Use-Lab GmbH, Steinfurt, Germany). Patient engagement and 
behaviour are becoming as critical to achieving successful health outcomes as safety and 
efficacy. This is probably even more important in paediatric medicines where both patients 
and care givers are involved with the administration process and often both play an active 
role. Dr Hermans unfolded the question on how do we design combination products for 
paediatric patients that help engage both caregivers and patients and enable ease of use, 
adherence and persistency? She presented the combination product development roadmap 
and illustrated with some examples on how to use the roadmap in the development process 
considering both the FDA and EMA requirements for dosing devices. Through the examples 
various concerns of the health authorities were discussed. Whereas, Mr Gruchmann shed the 
light on Human Factors (Usability) Engineering. He presented different methods that can be 
applied on Usability test design, testing environment and user groups. He further provided 
the detailed process and points to consider while performing the usability testing in children.  
 
The biopharmaceutics session chaired by Dr. Hannah Batchelor covered the issues with the 
strategies such as mixing medicine with food and drinks used to address the problem of 
administration of medicines to children due to the lack of age-appropriate oral formulations. 
Mixing medicine with food and drinks can affect medicine efficacy, dosing accuracy and 
bioavailability. Case study on managing food effects for paediatric was presented by Dr. David 
Harris (Merck & Co Inc., US). He illustrated the use of preclinical studies for evaluating 
paediatric formulations. Through case studies, general considerations on clinical tools for 
evaluating bioequivalence of paediatric formulations, food and vehicle effects were discussed. 
He also presented applications of modelling and simulation in paediatric drug development 
with a case study on use of Physiological Based Pharmacokinetic (PBPK) modelling to describe 
a formulation intended to be dosed with food in paediatrics. He concluded that preclinical in 
vivo studies provide a tool for screening formulations, food effects, and vehicle effects prior 
for improving clinical trial design. While clinical studies help characterize effects of 
formulation, food, and dosing vehicle in healthy adult subjects. The data from healthy adult 
subjects forms the basis of modelling and simulation studies to provide recommendations for 
paediatric PK and Phase III studies. Continuing on theme of using biopharmaceutical tools for 
evaluating paediatric formulations, Dr Nikoletta Fotaki gave a talk on predicting performance 
in paediatric populations with PBPK modelling and biorelevant in vitro data. She provided the 
overview on modelling of paediatric clinical data and matching to in vitro data. Ann Marie 
Kaukonen (Fimea Finnish Medicines Agency, Finland) provided the feedback from EuPFI – IQ 
/ M-CERSI workshop session on risk mitigation of food effects in paediatric medicines 
development for products co-administered with food. This workshop on ‘Challenges and 
Strategies to Facilitate Paediatric Drug Development’ took place in Baltimore US in June 2016. 
Dr. Trupti Dixit (Takeda Development Center Americas, US) presented the snapshot of this 
workshop. A short paper summarising the key take away points and next steps from 
MCERSI/IQ/EuPFI workshop is published in this special issue. Additionally, in depth discussions 
and case study outcomes from each session of workshop is captured in three manuscripts 
published as part of this special issue.  
 
The innovation shows case session was presented on “Novel Solutions for Pediatrics towards 
Better Compliance and Performance” by Edurado Jule from Capsugel and on “Chemistry 
Manufacturing and Controls Considerations in Pediatric Drug Formulation Development for 
Low Resource Setting Applications” by Stephen Gerrard from Bill Melinda Gates Foundation. 
The soapbox session, one of the popular sessions of the conference saw researchers 
presenting new ideas, innovative technologies and products in development. Attendees 
greatly enjoyed the fast pace of the Soapbox Sessions, along with the opportunity to meet 
one-on- one with those presenting Due to high quality poster and oral presentations, the 
Professional Compounding Centers of America (PCCA) sponsored and announced an 
additional oral presentation award this year making it upto 4 awards in total. 
 
The three poster awards were presented to: 
 Stefanie Keser, Development And Evaluation of Taste-Masked Pediatric Minitablet 
Formulations With Bitter Model Drugs. 
 Danielle Andrews, A Novel Approach To Assess And Improve Palatability Of An Inhaled 
Asset Using The Rat Brief Access Taste Aversion Assay And An In Silico Model Of 
Salivary Flow. 
 Frank Karkossa, Simulating Different Dosing Scenarios For A Paediatric Valproic Acid 
ER Formulation In A New Paediatric Multistage Dissolution Model. 
 and Oral presentation award was given to:  
 Felipe Lopez, Palatability and acceptability of multiparticulate formulations: adults vs. 
children comparison. 
 
The enaging and varied agenda was punctuated with social breaks and the guided Lisbon city 
tour allowing maximal interactions between participants.  
 
Once again this was a very successful meeting and hope has incentivized the participants to 
collaborate and work together towards formulating better medicines for children. We would 
like to thank our speakers, delegates, exhibitors and sponsors for their active contribution to 
the discussions in this meeting. The presentations, conference proceedings and picture gallery 
is posted on our website and is available at http://www.eupfi.org/past-conferences/8th-
eupfi-conference/. This special issue includes publications of selected presentations from the 
conference and accepted abstracts. 
 
What we all have to keep in mind is that collaboration among a broad range of disciplines and 
fostering a knowledge-sharing environment that places the patient's needs at the centre of 
paediatric drug development, consistent with science and risk-based approach, are the key 
gears of the path forward. Make sure you attend the next upcoming 9th EuPFI conference as 
continuation of collaborative efforts and to mark the 10th anniversary of the Paediatric 
Regulation and foundation of the EuPFI consortium. The conference will be held on 19th to 
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